CBS 2019
CBSMD教育中心
English

科学研究

科研文章

荐读文献

Frailty and Bleeding in Older Adults Undergoing TAVR or SAVR: Insights From the FRAILTY-AVR Study The Objective Physical Activity and Cardiovascular Disease Health in Older Women (OPACH) Study Percutaneous Coronary Intervention vs Coronary Artery Bypass Grafting in Patients With Left Main Coronary Artery Stenosis: A Systematic Review and Meta-analysis The prevalence and importance of frailty in heart failure with reduced ejection fraction - an analysis of PARADIGM-HF and ATMOSPHERE Transcatheter Aortic Valve Replacement in Low-risk Patients With Bicuspid Aortic Valve Stenosis Cardio-Oncology: How New Targeted Cancer Therapies and Precision Medicine Can Inform Cardiovascular Discovery Long-Term Outcomes of Anticoagulation for Bioprosthetic Valve Thrombosis Serial intravascular ultrasound assessment of very late stent thrombosis after sirolimus-eluting stent placement The Role of the Pericardium in Heart Failure: Implications for Pathophysiology and Treatment 2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines

Expert Opinion2017 Feb 28;135(9):819-821.

JOURNAL:Circulation Article Link

Percutaneous Coronary Intervention Versus Coronary Artery Bypass Grafting in Patients With Left Main and Multivessel Coronary Artery Disease: Do We Have the Evidence?

Gersh BJ, Stone GW, Bhatt DL et al. Keywords: coronary artery bypass grafting; coronary artery disease; stenting

ABSTRACT

Approximately 60 randomized controlled trials performed over the last 3 decades have failed to demonstrate statistically significant differences in death or myocardial infarction (MI) between coronary artery bypass grafting (CABG) and percutaneous coronary intervention (PCI), apart from a few notable exceptions in which CABG was superior to PCI. The benefits for CABG have been reported in patients with diabetes mellitus with multivessel disease and in patients with and without diabetes mellitus with 3-vessel disease and intermediate or high SYNTAX trial (Synergy between Percutaneous Coronary Intervention with Taxus and Cardiac Surgery) scores (≥23).